Keywords
Cardiotoxicity
Chemotherapy
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Select the scientific evidence produced on the early identification of heart failure induced by chemotherapy treatment and describe the relevant actions for implementing nursing care based on the selected evidence. Methods: This is an integrative review study, with articles published between 2012 and 2022 in Portuguese, English and Spanish. The bibliographic research was carried out in March 2023, on the data search platforms PubMed, Latin American and Caribbean Literature in Health Sciences (LILACS), and Scientific Electronic Library Online (SCIELO), with the Descriptors in Health Sciences (DeCS): Heart Failure, Cardiotoxicity, Chemotherapy, combining terms with the boolean operators “AND”, “NOT”, “OR”. The guiding question was applied: What are the good practices evidenced in the literature for the early identification of heart failure induced by chemotherapy drugs, for nurses to perform? Results: 43 articles met the inclusion and exclusion criteria, in which the nurse plays an important role before, during and after chemotherapy treatment. Final considerations: It is considered that early identification by nurses is essential to the care of patients undergoing chemotherapy treatment, consolidating its importance in multidisciplinary work for the adequate, safe and preventive management of these patients.
References
AGUNBIADE TA, et al. Heart Failure in Relation to Anthracyclines and Other Chemotherapies. Methodist DeBakey Cardiovascular Journal, 2019; 15(4): 243–249.
ANAKWUE R. Cytotoxic-induced heart failure among breast cancer patients in Nigeria: A call to prevent today's cancer patients from being tomorrow's cardiac patients. Annals of African Medicine, 2020; 19(1): 1–7.
ANKER MS, et al. Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'. ESC Heart Fail. 2019; 6(6): 1140-1148.
ÁVILA MR, et al. Disfunção Ventricular Assintomática e Insuficiência Cardíaca com Fração de Ejeção Reduzida Secundária à Quimioterapia Clássica. ABC Heart Failure & Cardiomyopathy, 2022; 2(4): 335-42.
BERGLER-KLEIN, et al. Cardio-oncology in Austria: cardiotoxicity and surveillance of anticancer therapies: Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology. Wiener klinische Wochenschrift, 2022; 134(17-18): 654–674.
CARDINALE D, et al. Early Detection of Anthracycline Cardiotoxicity and Improvement with Heart Failure Therapy. Circulation, 2015; 131(22).
CELESTE, LEN., e MAIA, MR. Cuidados de enfermagem relacionados à cardiotoxicidade envolvendo drogas como as antraciclinas e anticorpos monoclonais no tratamento oncológico. PubSaúde, 2021; 5: 095.
CLASEN SC, WALD JW. Left Ventricular Dysfunction and Chemotherapy Agents. Current Cardiology Reports, 2018; 20(4): 20.
DOMINGUEZ, JAP et al. Factores de riesgo de cardiotoxicidad precoz por quimioterapia en pacientes con cáncer de mama. Multimed Epub, 2022; 26(3).
DUARTE EC, BARRETO SM. Transição demográfica e epidemiológica: a Epidemiologia e Serviços de Saúde revisita e atualiza o tema. Epidemiologia e Serviços de Saúde, 2012; 21(4): 529-532.
ELIZALDE AIG, et al. Recomendaciones para el manejo de la cardiotoxicidad relacionada con el tratamiento del cáncer. Primera parte. Revista Uruguaya de Cardiología, 2021; 36(1): 36107.
FERREIRA SMA, et al. Insuficiência Cardíaca Avançada no Paciente com Câncer. ABC Heart Failure & Cardiomyopathy, 2022; 2(4): 395-7.
FIGUEROA JR, CARDÓS RC. Importance of cardio-oncology. How to detect subclinical heart failure. Archivos de Cardiología de México, 2021; 91(2): 229-234.
HAJJAR LA, et al. Diretriz Brasileira de Cardio-oncologia – 2020. Arquivo Brasileiro de Cardiologia., 2020; 115(5): 1006-1043.
HENRY ML, et al. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC. Cardiovascular Imaging, 2018; 11(8): 1084–1093.
JORGE AJL, et al. Insuficiência Cardíaca com Fração de Ejeção Preservada e Câncer. ABC Heart Failure & Cardiomyopathy, 2022; 2(4): 343-5.
JESUS, EB de. Protocolo assistencial de enfermagem para avaliação e manejo de pacientes adultos submetidos à terapia oncológica cardiotóxica: estudo metodológico. Dissertação (Mestrado em Enfermagem) - Universidade Federal Fluminense, Niterói, 2019; 172.
LONG HD, et al. Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis. The Oncologist, 2016; 21(5): 547–554.
MADEDDU C, et al. Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. Journal of cardiovascular medicine (Hagerstown, Md.), 2016; 17(1): 12–18. Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection.
MARTÍNEZ FLM, et al. Utilidad de las técnicas de deformación miocárdica (strain) para evaluar cardiotoxicidad en pacientes con enfermedades oncológicas y tratamiento quimioterápico. CorSalud: Revista de Enfermedades Cardiovasculares, 2021; 13(1): 44-50.
MONSUEZ JJ. Detection and Prevention of Cardiac Complications of Cancer Chemotherapy. Archives of Cardiovascular Diseases, 2012; 105(11): 593–604.
OHTANI K, et al. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity. Clinical Research in Cardiology, 2019; 108(6): 600–611.
OPAS. OMS revela as principais causas de morte e incapacidade em todo o mundo entre 2000 e 2019 [9/12/2020]. Disponível em: https ://www.paho.org/pt/noticias/9-12-2020. Acessado em: 18 de junho de 2022.
POLONSKY TS, DECARA JM. Risk factors for chemotherapy-related cardiac toxicity. Current Opinion in Cardiology, 2019; 34(3): 283–288.
RAMOS MAR. Estratificación del riesgo de cardiotoxicidad inducida por quimioterapia. CorSalud: Revista de Enfermedades Cardiovasculares, 2018; 10(4): 341-342.
ROSA PR, et al. Severe cardiac insufficiency secondary to cardiotoxicity with clinical and morpho-functional improvement after optimized clinical treatment: case report. Bioscience Journal, 2020; 36(6): 2281-2287.
SANTOS MVC dos, et al. Cardio-Oncologia no Brasil: Cenário Atual e Perspectivas. Revista Brasileira de Cancerologia, 2019; 65(3): 00852.
SCARABELLI CC e SCARABELLI TM. Heart Failure Progression During Cardiotoxic Chemotherapy. JACC. Heart Failure, 2019; 7(4): 365–367.
SILVA JMD, et al. Cardiovascular adverse events associated with oral antineoplastic therapy. Revista Brasileira de Enfermagem, 2018; 71(5): 2561-2569.
SVOBODA M, et al. Cardiac Toxicity of Targeted Therapies Used in the Treatment of Solid Tumors: A Review. Cardiovascular Toxicology, 2012; 12(3): 191–207.
VALENTE PMS, et al. Pesquisa de cardiotoxicidade em prontuário de paciente submetido à quimioterapia R-CHOP: um estudo de caso. Revista Brasileira de Cancerologia, 2019; 65(3).